If you liked this article you might like

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk
Medivation Founder Takes Helm at Axovant, Shares Spike
Second-Quarter Picks and Pans
How I'd Play Biotech Buyout Rumors